Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal mitoxantrone hydrochloride + pegaspargase
- Development stage
- Unknown
- Lead developer
- CSPC ZhongQi Pharmaceutical Technology
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular
01
Overview
Liposomal mitoxantrone hydrochloride + pegaspargase is a combination therapy under investigation primarily for the treatment of relapsed or refractory peripheral T-cell lymphoma and extranodal NK/T-cell lymphoma. Liposomal mitoxantrone is a formulation of the anthracenedione antineoplastic agent, encapsulated in a lipid bilayer to improve pharmacokinetics and reduce toxicity. It acts as a DNA intercalator and type II DNA topoisomerase inhibitor, disrupting DNA synthesis and repair in cancer cells[6][8]. Pegaspargase is an enzyme that depletes asparagine by converting it to aspartic acid, exploiting the inability of certain leukemia/lymphoma cells to synthesize asparagine, leading to cell death[2][5]. The combination aims to enhance efficacy while minimizing side effects compared with standard regimens. CSPC Pharmaceutical Group has filed patents for this combination specifically targeting NK/T-cell lymphomas[4].
- Brand names
- OncasparDuoenda
- Other names
- pegylated liposomal mitoxantrone
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on liposomal mitoxantrone hydrochloride + pegaspargase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal mitoxantrone hydrochloride + pegaspargase.